Home » Topics » Disease categories and therapies » Cancer

Cancer
RSS

TAK-733 has potent antitumor activity in vivo

March 1, 2011

Ipsen and bioMerieux partner for personalized cancer medicine

March 1, 2011

Volasertib is active as second-line therapy for urothelial cancer in phase II trial

March 1, 2011

New protein kinase inhibitors disclosed

Feb. 28, 2011

Takeda presents novel PARP inhibitors

Feb. 28, 2011

FDA grants Genentech hearing on Avastin for metastatic breast cancer

Feb. 28, 2011

Phase II TXA-127 trial begins in autologous peripheral blood stem cell transplantation

Feb. 28, 2011

MolMed extends pivotal phase III trial of NGR-hTNF

Feb. 28, 2011

AMG-386/sorafenib combination shows promise in metastatic renal cell carcinoma

Feb. 28, 2011

CEQ-508 does not have adverse effects in nonhuman primates

Feb. 28, 2011

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 12, 2026.
Europe’s Alzecure, Orionis in $1B+ deals with Lilly, Novartis
BioWorld
Two companies with European ties signed billion-dollar deals with large pharma firms in the last two days to discover and develop molecular glue drugs, as well as...
Ethyreal launches to treat the underlying cause of Graves’, TED
BioWorld
Ethyreal Bio Inc. has come out of stealth mode in order to disclose preclinical data for ETHY-001, its monoclonal antibody targeting thyroid stimulating hormone...
Sanofi phase III CIDP quit dents Dianthus; C1 mismatch?
BioWorld
Investors in Dianthus Therapeutics Inc. apparently chose to ignore subtleties in the difference between efforts with that firm’s claseprubart vs. those by...
Jiangsu Nhwa Pharmaceutical patents new κ-opioid receptor antagonists
BioWorld Science
Jiangsu Nhwa Pharmaceutical Co. Ltd. has disclosed κ-opioid receptor antagonists that are potentially useful for the treatment of neurological disorders.